Since the present studies were designed to examine the direct pathophysiologic effects of elevated plasma renin activity in HFrEF progression, they do not provide insights into how DRI monotherapy compares to other HF therapies with or without co-administration of DRI. The gene discussed is REN; the disease is hydrops fetalis.